XML 26 R17.htm IDEA: XBRL DOCUMENT
v3.22.2

Legal Settlements and Loss Contingencies | 6 Months Ended
--- | ---
Jun. 30, 2022
Legal Settlements and Loss Contingencies | NOTE 9 – Legal settlements and loss contingencies: In the second quarter of 2022, Teva recorded expenses of $729 million in legal settlements and loss contingencies, compared to $6 million in the second quarter of 2021. The expenses in the second quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. See note 10. In the first six months of 2022, Teva recorded an expense of $1,854 million in legal settlements and loss contingencies, compared to an expense of $110 million in the first six months of 2021. The expense in the first six months of 2022 was mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. The expense in the first six months of 2021 was mainly due to the provision for the carvedilol patent litigation. As of June 30, 2022 and December 31, 2021, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $3,928 million and $2,710 million, respectively. In connection with Teva’s provision for legal settlements and loss contingencies as of December 31, 2021, related to the Ontario Teachers Securities Litigation, Teva also recognized an insurance receivable.

X
- Definition The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -URI https://asc.fasb.org/topic&trid=2127136 + Details
Name: | us-gaap_LegalMattersAndContingenciesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration